The Lancet Highlights Global Rise in Counterfeit Anti-Obesity Drugs and Health Risks

The Lancet reports a growing global issue of counterfeit anti-obesity drugs, including semaglutide, detected in at least 11 countries. These fake medications, often sold through unregulated online markets, may contain harmful substances such as high-dose insulin or bacteria, posing serious health risks including fatal hypoglycemia. The surge in demand driven by drug effectiveness, celebrity endorsements, and supply shortages has enabled counterfeiters to exploit patients seeking weight loss solutions, highlighting gaps in supply chain safeguards.